1. Page, Brent D G, Valerie, Nicholas C K, Wright, Roni H G, Beato, Miguel, Helleday, Thomas. 2018. Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. In Nature communications, 9, 250. doi:10.1038/s41467-017-02293-7. https://pubmed.ncbi.nlm.nih.gov/29343827/
2. Li, Dan-Ni, Yang, Cheng-Cheng, Li, Jin, Cui, Ju, Cai, Jian-Ping. 2020. The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancer. In Biochimica et biophysica acta. Molecular cell research, 1868, 118895. doi:10.1016/j.bbamcr.2020.118895. https://pubmed.ncbi.nlm.nih.gov/33096144/
3. Zhang, He, Zhang, Li-Qun, Yang, Cheng-Cheng, Cui, Ju, Cai, Jian-Ping. 2021. The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling. In PloS one, 16, e0245876. doi:10.1371/journal.pone.0245876. https://pubmed.ncbi.nlm.nih.gov/33571243/
4. Sultana, Razia, Islam, Monjia, Haque, Md Azizul, Khanom, Jabunnesa, Munim, Md Adnan. 2019. Molecular docking based virtual screening of the breast cancer target NUDT5. In Bioinformation, 15, 784-789. doi:10.6026/97320630015784. https://pubmed.ncbi.nlm.nih.gov/31902977/
5. Tian, Yin, Chen, Li'e, Jiang, Yun. 2023. LASSO-based screening for potential prognostic biomarkers associated with glioblastoma. In Frontiers in oncology, 12, 1057383. doi:10.3389/fonc.2022.1057383. https://pubmed.ncbi.nlm.nih.gov/36733371/